1887

Journal of Medical Microbiology logo

Volume 67, Issue 9

High rates of Mycobacterium fortuitum isolation in respiratory samples from Iranian patients with suspected tuberculosis: is it clinically important? Free

Abstract

Purpose. Although Mycobacterium fortuitum (M. fortuitum) is not an organism rarely isolated from respiratory samples, its clinical importance is still not fully understood, which therefore prompted our current study.

Methodology. We evaluated respiratory samples from 6800 patients with suspected tuberculosis from May 2014 to May 2016, for the detection of M. fortuitum using phenotypic and genotyping methods.

Results/Key findings. Of the 40 patients with M. fortuitum lung disease, 35 had two or more positive culture results. The mean age of these 35 patients was 50.7±18.4 years, and 20 (57.1 %) were men. Sputum (68.6 %), haemoptysis (51.4 %), cough (45.7 %) and gastroesophageal disease (22.9 %) were the major presenting symptoms. Cystic fibrosis, other bacterial lung diseases and lung cancer were the main underlying pulmonary diseases. Five patients (12.5 %) were human immunodeficiency virus (HIV) positive. The most common chest X-ray findings were reticulonodular opacities (53.3 %). Multivariate logistic regression analysis revealed that cigarette smoking history (OR 0.334, 95 % CI 0.125–0.843, P=0.048) and underlying lung disease (OR 0.393, 95 % CI 0.216–0.588, P=0.023) were significant predictors for positive M. fortuitum infection.

Conclusion. These results demonstrated the high frequency of M. fortuitum in respiratory samples and that this bacterium causes transient infection or colonization in patients with underlying pulmonary conditions, such as cystic fibrosis and cigarette smoking-induced. Additionally, it appears that infection with M. fortuitum is particularly common and may be important in patients with HIV.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): human immunodeficiency virus , lung disease and Mycobacterium fortuitum
© 2018 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000814
2018-07-27
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/67/9/1243.html?itemId=/content/journal/jmm/10.1099/jmm.0.000814&mimeType=html&fmt=ahah

References

  1. Velayati AA, Rahideh S, Nezhad ZD, Farnia P, Mirsaeidi M. Nontuberculous mycobacteria in Middle East: current situation and future challenges. Int J Mycobacteriol 2015; 4:7–17 [View Article][PubMed]
     [Google Scholar]
  2. Nour-Neamatollahie A, Ebrahimzadeh N, Siadat SD, Vaziri F, Eslami M et al. Distribution of non-tuberculosis mycobacteria strains from suspected tuberculosis patients by heat shock protein 65 PCR-RFLP. Saudi J Biol Sci 2017; 24:1380–1386 [View Article][PubMed]
     [Google Scholar]
  3. Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL. Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis 2009; 49:e124-9 [View Article][PubMed]
     [Google Scholar]
  4. Miguez-Burbano MJ, Flores M, Ashkin D, Rodriguez A, Granada AM et al. Non-tuberculous mycobacteria disease as a cause of hospitalization in HIV-infected subjects. Int J Infect Dis 2006; 10:47–55 [View Article][PubMed]
     [Google Scholar]
  5. Thomas R, Pega F, Khosla R, Verster A, Hana T et al. Ensuring an inclusive global health agenda for transgender people. Bull World Health Organ 2017; 95:154–156 [View Article][PubMed]
     [Google Scholar]
  6. Zheng HW, Pang Y, He GX, Song YY, Zhao YL. Antimicrobial susceptibility testing and molecular characterization of Mycobacterium fortuitum isolates in China. Biomed Environ Sci 2017; 30:376–379 [View Article][PubMed]
     [Google Scholar]
  7. Khoshneviszadeh M, Edraki N, Javidnia K, Alborzi A, Pourabbas B et al. Synthesis and biological evaluation of some new 1,4-dihydropyridines containing different ester substitute and diethyl carbamoyl group as anti-tubercular agents. Bioorg Med Chem 2009; 17:1579–1586 [View Article][PubMed]
     [Google Scholar]
  8. Fassihi A, Azadpour Z, Delbari N, Saghaie L, Memarian HR et al. Synthesis and antitubercular activity of novel 4-substituted imidazolyl-2,6-dimethyl-N3,N5-bisaryl-1,4-dihydropyridine-3,5-dicarboxamides. Eur J Med Chem 2009; 44:3253–3258 [View Article][PubMed]
     [Google Scholar]
  9. Kent PT, Kubica GP. US Centers for Disease Control and Prevention Public health mycobacteriology: a guide for the level III laboratory: Atlanta, GA, US Department of Health and Human Services, Public Health Service, Centers for Disease Control; 1985
  10. Telenti A, Marchesi F, Balz M, Bally F, Böttger EC et al. Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol 1993; 31:175–178[PubMed]
     [Google Scholar]
  11. Gutell RR. Collection of small subunit (16S- and 16S-like) ribosomal RNA structures. Nucleic Acids Res 1993; 21:3051–3054 [View Article][PubMed]
     [Google Scholar]
  12. Adékambi T, Colson P, Drancourt M. rpoB-based identification of nonpigmented and late-pigmenting rapidly growing mycobacteria. J Clin Microbiol 2003; 41:5699–5708 [View Article][PubMed]
     [Google Scholar]
  13. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367–416 [View Article][PubMed]
     [Google Scholar]
  14. Park S, Suh GY, Chung MP, Kim H, Kwon OJ et al. Clinical significance of Mycobacterium fortuitum isolated from respiratory specimens. Respir Med 2008; 102:437–442 [View Article][PubMed]
     [Google Scholar]
  15. Hand WL, Sanford JP. Mycobacterium fortuitum–a human pathogen. Ann Intern Med 1970; 73:971–977 [View Article][PubMed]
     [Google Scholar]
  16. Bevelaqua FA, Kamelhar DA, Campion J, Christianson LC. Mycobacterium fortuitum-chelonei; two patients with fatal pulmonary infection. N Y State J Med 1981; 81:1621–1624[PubMed]
     [Google Scholar]
  17. Efthimiou J, Smith MJ, Hodson ME, Batten JC. Fatal pulmonary infection with Mycobacterium fortuitum in cystic fibrosis. Br J Dis Chest 1984; 78:299–302 [View Article][PubMed]
     [Google Scholar]
  18. Jouannic I, Desrues B, Léna H, Quinquenel ML, Donnio PY et al. Exogenous lipoid pneumonia complicated by Mycobacterium fortuitum and Aspergillus fumigatus infections. Eur Respir J 1996; 9:172–174[PubMed]
     [Google Scholar]
  19. Jacobson K, Garcia R, Libshitz H, Whimbey E, Rolston K et al. Clinical and radiological features of pulmonary disease caused by rapidly growing mycobacteria in cancer patients. Eur J Clin Microbiol Infect Dis 1998; 17:615–621 [View Article][PubMed]
     [Google Scholar]
  20. Noone PG, Leigh MW, Sannuti A, Minnix SL, Carson JL et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004; 169:459–467 [View Article][PubMed]
     [Google Scholar]
  21. Ehrmantraut M, Hillingoss D, Chernick M, Steagall W, Glasgow C et al. Pulmonary nontuberculous mycobacterium infections are highly associated with mutations in CFTR. Am J Respir Crit Care Med 2003; 167:A708
     [Google Scholar]
  22. Hadjiliadis D, Adlakha A, Prakash UB. Rapidly growing mycobacterial lung infection in association with esophageal disorders. Mayo Clin Proc 1999; 74:45–51 [View Article][PubMed]
     [Google Scholar]
  23. Duan H, Han X, Wang Q, Wang J, Wang J et al. Clinical significance of nontuberculous Mycobacteria isolated from respiratory specimens in a Chinese tuberculosis tertiary care center. Sci Rep 2016; 6:36299 [View Article][PubMed]
     [Google Scholar]
  24. Radzniwan MR, Tohid H, Ahmad S, Mohd AF, Md Anshar F. Isolation of Mycobacterium fortuitum in sputum specimens of a patient with chronic cough: is it clinically significant?. Malays Fam Physician 2014; 9:38–41[PubMed]
     [Google Scholar]
  25. Yano Y, Kitada S, Mori M, Kagami S, Taguri T et al. Pulmonary disease caused by rapidly growing mycobacteria: a retrospective study of 44 cases in Japan. Respiration 2013; 85:305–311 [View Article][PubMed]
     [Google Scholar]
  26. Smith MB, Schnadig VJ, Boyars MC, Woods GL. Clinical and pathologic features of Mycobacterium fortuitum infections. Am J Clin Pathol 2001; 116:225–232 [View Article]
     [Google Scholar]
  27. Thomson RM, Yew WW. When and how to treat pulmonary non-tuberculous mycobacterial diseases. Respirology 2009; 14:12–26 [View Article][PubMed]
     [Google Scholar]
  28. Field SK, Cowie RL. Lung disease due to the more common nontuberculous mycobacteria. Chest 2006; 129:1653–1672 [View Article][PubMed]
     [Google Scholar]
  29. Chung MJ, Lee KS, Koh WJ, Lee JH, Kim TS et al. Thin-section CT findings of nontuberculous mycobacterial pulmonary diseases: comparison between Mycobacterium avium-intracellulare complex and Mycobacterium abscessus infection. J Korean Med Sci 2005; 20:777–783 [View Article][PubMed]
     [Google Scholar]
  30. Matsumoto T, Otsuka K, Tomii K. Mycobacterium fortuitum thoracic empyema: a case report and review of the literature. J Infect Chemother 2015; 21:747–750 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000814
Loading
High rates of Mycobacterium fortuitum isolation in respiratory samples from Iranian patients with suspected tuberculosis: is it clinically important?
J. Med. Microbiol. 67, 1243 (2018); https://doi.org/10.1099/jmm.0.000814
/content/journal/jmm/10.1099/jmm.0.000814
/content/journal/jmm/10.1099/jmm.0.000814
Loading

Data & Media loading...

Supplements

Supplementary File 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error